Understand the importance of a clinical approach in pain pharmacology to enhance treatment effectiveness and patient care.

07-21 Educational Guide: Integrative Pharmacology and Chiropractic Pain Management — Dr. Alex Jimenez and Multidisciplinary Protocols

Abstract

Pain is not a single signal or a simple sensation; it is a dynamic, biopsychosocial process shaped by peripheral inflammation, central sensitization, and descending modulation. I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this educational post, I guide you through a comprehensive, evidence-based pain care strategy that integrates pharmacology, integrative chiropractic care, functional medicine, and rehabilitation within a multidisciplinary clinic. At Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, I collaborate daily with Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), our Medical Director and Collaborative Physician with over 40 years of experience. Together, we deliver coordinated, mechanism-driven treatment plans that align medications such as acetaminophen, NSAIDs, topical agents, anticonvulsants, antidepressants, muscle relaxants, and opioids with hands-on chiropractic interventions, movement retraining, medical nutrition therapy, and behavioral health support. We explain how the cytochrome P450 system influences opioid choices, why gabapentinoids and SNRIs target central sensitization and descending inhibition, when topical therapies rival systemic options, how low-dose naltrexone modulates microglia, and where novel agents like suzetrigine fit for acute pain. This guide details protocols, physiology, dosing logic, risk mitigation, and real-world clinical observations from my work documented at HealthCoach Clinic and my professional updates on LinkedIn. It is designed to empower patients and clinicians with clear reasoning and practical steps grounded in modern research methods and rigorous evidence.

Meet Our Integrated Care Team: A Coordinated Model for Safer, Smarter Pain Care

Hello, I am Dr. Alex Jimenez, and my clinical mission is to blend the best of integrative chiropractic care with the precision of internal medicine and the metabolic insight of functional medicine to help people move, heal, and thrive. Our practice, Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas, is intentionally structured as a multidisciplinary team so that each patient benefits from coordinated expertise.

• Medical direction and oversight: Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), with over 40 years as an internist, serves as Medical Director and Collaborative Physician.
• Chiropractic care and rehabilitation: I lead integrative chiropractic services—spinal and extremity adjustments, mobilization, soft-tissue release, decompression strategies, graded exposure, and movement retraining—integrated with my advanced training as an APRN and FNP-BC.
• Functional medicine: We address the gut-liver axis, systemic inflammation, glycemic control, micronutrient status, and sleep-circadian health to improve pain physiology and recovery capacity.
• Personal injury care: We provide documentation of mechanism of injury, impairment ratings, and return-to-function plans.
• Behavioral health and specialty referrals: When needed, we coordinate cognitive behavioral therapy (CBT, ACT), neurology, pain specialists, surgery, and interventional procedures.

This is the kind of integrated environment often found in progressive injury and integrative clinics: an MD provides medical direction alongside a chiropractor to align therapies, mitigate risks, and optimize outcomes.

Why Expectations Matter in Pain Care: From Binary Relief to Layered Wins

I often remind patients: pain relief is rarely all-or-nothing. Clinically meaningful improvement is often defined as a 30–60 percent reduction in pain or a comparable gain in function (e.g., increased walking time, improved sleep continuity). If the expectation is 100 percent relief, anything less can feel like failure. In our clinic, we:

• Set realistic goals (e.g., lift a grocery bag without flare, walk 20 minutes without stopping).
• Measure progress using validated tools like the Brief Pain Inventory and PROMIS interference scales (Cleeland, 2009).
• Highlight layered progress (e.g., “We got 20 percent from topical NSAID, 30 percent from duloxetine, and 10 percent by improving sleep—together these wins change your day-to-day life.”).

Shifting from “pain score only” to “function plus pain” transforms the experience and sustains adherence.

Functional Metrics That Matter: Beyond the 0–10 Pain Scale

A 10/10 pain while immobile is different from a 10/10 after walking with a grandchild. Numbers without context can mislead. We emphasize:

• Function-focused outcomes: walking duration, stair navigation, ability to sit through dinner, lifting thresholds.
• Activity-based grading: graded exposure with symptom tracking during and after tasks.
• Recovery behaviors: adherence to exercises, flare strategies, sleep hygiene, pacing.

This functional lens guides each step of care—including medication titration and manual therapy progression.

The Physiology of Pain: Foundations for Targeted Therapy

To choose any therapy with confidence, we must map it to pain physiology. Here is the essence:

• Peripheral sensitization: Inflammatory mediators (prostaglandins, bradykinin, histamine, cytokines like IL-1?, TNF-?, and NGF) lower nociceptor thresholds. Result: more firing, more pain.
• Central sensitization: Dorsal horn neurons become hyper-responsive; NMDA receptors augment synaptic efficacy while inhibitory interneuron function may wane—driving hyperalgesia and allodynia (Woolf, 2011).
• Descending modulation: The brainstem’s serotonergic and noradrenergic systems (periaqueductal gray and rostral ventromedial medulla) inhibit or facilitate nociception. SNRIs/TCAs can amplify inhibition (Millan, 2002).
• Neuroimmune crosstalk: Microglia and astrocytes influence chronic pain via cytokine and chemokine signaling (Grace et al., 2014).
• Biopsychosocial integration: Catastrophizing, fear-avoidance, poor sleep, deconditioning, and autonomic dysregulation amplify pain and disability.

Mechanism-to-treatment mapping:

• NSAIDs: inhibit prostaglandin synthesis (peripheral inflammation).
• Acetaminophen: modulates central pathways (COX variants, serotonergic, endocannabinoid/AM404) with debated mechanisms.
• Anticonvulsants (gabapentinoids): dampen excitatory neurotransmission and calcium channel activity—blunting central sensitization.
• Antidepressants (SNRIs, TCAs): reinforce descending inhibition (serotonin/norepinephrine).
• Topicals (diclofenac, lidocaine, capsaicin): peripheral modulation with reduced systemic risks.
• Opioids: mu receptor activation with careful pharmacokinetic/pharmacogenetic consideration.

We select tools that fit the mechanism driving a patient’s pain pattern.

Integrative Chiropractic Care: Mechanobiology That Calms Nerves and Restores Movement

Manual therapy is not just about joints; it is neurobiological:

• Segmental mobility: Restoring normal joint motion reduces nociceptive input from capsules, ligaments, and musculotendinous units.
• Central modulation: Joint and soft-tissue techniques enhance mechanoreceptive input (A? fibers) that can gate nociception at the dorsal horn; they may also influence supraspinal centers to boost descending inhibition (Bialosky et al., 2009).
• Movement retraining: Corrective exercises normalize load and improve neuromuscular control, addressing root mechanical drivers.
• Autonomic balance: Breathing and posture can modulate sympathetic arousal, reducing pain amplification.
• Functional wins: Improved mechanics make daily loading safer, accelerating return to preferred activities.

Dr. Cardenas ensures medical safety before we blend medications and manual interventions—addressing anticoagulation, bone health, canal stenosis, radiculopathy severity, and systemic disease.

Acetaminophen: Central Modulation, Hepatic Safety, and Smart Use

Mechanistic nuance:

• Central COX and serotonergic modulation with potential endocannabinoid effects via AM404 metabolite (Roberts et al., 2016; Högestätt et al., 2005; Pini et al., 1997).
• Limited peripheral anti-inflammatory activity.

Safety considerations:

• Hepatotoxicity above 4 g/day; risk increases with alcohol use, liver disease, malnutrition, and CYP2E1 induction (Lee, 2017).
• Education on “hidden” acetaminophen in combination products is essential.

Clinical approach:

• Start with modest dosing in mild to moderate pain or when NSAIDs are contraindicated.
• Monitor LFTs in higher-risk patients.
• Use as a “bridge” to facilitate movement practice and manual care by lowering baseline pain enough to reduce guarding.

Why use it: It is a low-friction tool for central analgesia that pairs well with exercise therapy and chiropractic adjustments when safely dosed.

NSAIDs: Precision Use Balancing Inflammation, GI and CV Risk

Core pharmacology:

• COX-1 and COX-2 inhibition reduces prostaglandin synthesis to curb inflammation and pain.

Evidence and risk:

• No single NSAID is universally superior; individual response varies.
• GI harm is systemic, not just local; COX-1 inhibition reduces mucosal protection (Lanas & Chan, 2017).
• High-dose ibuprofen can cause GI bleeding in 3–5 days in healthy volunteers (Bjarnason et al., 2018).
• Cardiovascular risks exist across many NSAIDs; some COX-2 selective agents reduce GI risk but not CV risk (Bhala et al., 2013).
• Combined with infection or aspirin, risks escalate.

Clinical implementation:

• Match NSAID choice to patient profile: meloxicam for OA, naproxen for balanced risk, diclofenac for strong anti-inflammatory action with GI vigilance, celecoxib for higher GI risk if CV risk is appropriate.
• Shortest duration at the lowest effective dose with gastroprotection where indicated (recognizing PPIs mainly protect the stomach, not the small bowel).
• Monitor BP and renal function (serum creatinine, eGFR).

Integrative fit: For inflammatory flares, NSAIDs can enable manual therapy and graded exercise by reducing peripheral nociception—always framed as temporary support rather than a long-term solution.

Topical Analgesics: Peripheral Relief, Minimal Systemic Burden

Why I often start here: Topicals allow us to intercept the pain cascade at the source with less systemic exposure.

• Topical NSAIDs (diclofenac gel/patches): robust for superficial joints and tendinopathies with reduced GI/CV risk (Derry et al., 2016).
• Lidocaine patches: sodium channel blockade to diminish ectopic discharges; beneficial for localized neuropathic pain (Khaliq et al., 2007).
• Capsaicin: TRPV1 agonism leading to nociceptor defunctionalization with repeated or high-concentration application; helpful for neuropathic pain (Eccles & Turner, 2009).

Clinical tactics:

• Apply directly over symptomatic zones guided by palpation and patient feedback.
• Use pre-activity to unlock movement and post-treatment to sustain gains.
• Combine lidocaine and capsaicin cycles when tolerated for neuropathic patterns.

Rationale: Topicals offer a targeted approach that pairs well with chiropractic care and rehab, particularly for high-risk patients where systemic drugs pose hazards.

The Journey of a Pain Signal: Opportunities for Intervention

I explain to patients that pain has three stages:

• Transduction: Chemical mediators in injured tissue activate nociceptors.
• Transmission: Signals travel through peripheral nerves to the dorsal horn and ascend the neuraxis.
• Perception: The brain evaluates, contextualizes, and feels pain—modulated by emotion, cognition, and prior experiences.

Each stage provides therapeutic targets:

• Block or modulate transduction (topical NSAIDs, capsaicin).
• Dampen transmission (lidocaine patches, gabapentinoids).
• Enhance central inhibition (SNRIs, TCAs) and improve cortical processing through education, sleep, and movement.

This framework makes multi-mechanistic care logical and convincing for patients.

Anticonvulsants as Nerve Membrane Stabilizers: Calming the “Quivering” Neuron

When nerves are injured or persistently irritated, they can become hyperexcitable—”quivering” at minimal provocation. I teach patients to see gabapentinoids as nerve membrane stabilizers, not just pain pills.

• Gabapentin and pregabalin bind the alpha-2-delta subunit of voltage-gated calcium channels, reducing presynaptic release of excitatory neurotransmitters (Taylor et al., 2007).
• This “dimmer switch” effect helps reduce wind-up and central sensitization.
• Glial modulation has been suggested for gabapentin, hinting at anti-inflammatory neural effects.

Clinical approach to gabapentin:

• Start low, go slow to minimize dizziness, somnolence, and cognitive fog.
• Recognize decreasing bioavailability at higher doses due to saturable transport—avoid reflexive escalation when limited marginal benefit appears.
• Adjust for renal function.
• Be mindful of rare but serious DRESS syndrome and medication-induced central sleep apnea; screen for sleep-disordered breathing.

Pregabalin:

• Linear pharmacokinetics, faster onset, but watch for weight gain and edema.
• Many patients reach a functional therapeutic ceiling around 450 mg/day, with side effects rising faster beyond that.

Important safety note on long-term gabapentinoids:

• Literature highlights misuse/abuse potential and emerging cardiovascular concerns in certain populations (Goodman & Brett, 2019; Evoy et al., 2021). While further high-quality research is needed for definitive causation, I discuss potential long-term risks transparently and emphasize periodic reevaluation, especially in patients with CV risk factors.

Integration with chiropractic: By reducing baseline neural hyperexcitability, these agents can open a window for graded exposure, sensorimotor retraining, and manual therapy—accelerating desensitization through movement.

Antidepressants as True Analgesics: Reinforcing the Brain’s Own Brake System

SNRIs and TCAs are not just for mood; they are central analgesics with proven efficacy in patients without depression.

Mechanisms:

• SNRIs (duloxetine, venlafaxine) and TCAs (amitriptyline, nortriptyline) enhance descending inhibitory pathways by increasing serotonin and norepinephrine signaling (Millan, 2002; Moore et al., 2015).
• TCAs also exert sodium channel and NMDA antagonism, aiding neuropathic pain and sleep consolidation.

Duloxetine: a standout for chronic musculoskeletal pain

• Evidence supports duloxetine for knee osteoarthritis and chronic low back pain, improving pain and function within weeks (Gatti et al., 2021; Chappell et al., 2011).
• Start 30 mg daily for one week, then 60 mg daily; proactively manage nausea (ondansetron prescription if needed).
• Particularly useful when NSAIDs are contraindicated (e.g., GI bleeds, CKD, anticoagulation).

TCAs: low-dose power

• Start nortriptyline or amitriptyline at 10 mg nightly; many patients do well between 10–50 mg.
• Monitor anticholinergic effects; consider baseline ECG in older adults or cardiac risk.
• Especially helpful for neuropathic pain phenotypes and insomnia.

Clinical pearls:

• Milnacipran is fibromyalgia-specific and more noradrenergic—watch for activation.
• Venlafaxine has weaker pain data; consider if already used for mood and providing ancillary benefit.

Serotonin syndrome awareness:

• Rare but serious; use the Hunter Criteria for structured assessment; clonus and hyperreflexia are key (Goodman & Brett, 2019).
• Onset usually occurs within hours after starting or increasing a serotonergic agent; chronic stable dosing rarely precipitates it.

Black box warning context:

• Original suicidality signals were primarily in children and adolescents; older adults (>65) may derive protective effects, but vigilance is always warranted (FDA, 2018).

Integration with chiropractic: Improving sleep and mood fortifies descending inhibition—patients tolerate manual therapy better and engage more consistently in rehabilitation.

Muscle Relaxants: When Sedation Is Not a Solution

Muscle relaxants have limited roles, especially for sciatica and radicular pain.

• Many are centrally acting sedatives (e.g., cyclobenzaprine resembles a TCA), shifting perception more than fixing mechanical or neuropathic drivers (Browning et al., 2001).
• Tizanidine (alpha-2 agonist) may help when spasticity is a feature; monitor for hypotension and sedation (Smith & Laufer, 2010).
• Diazepam offers little benefit for acute low back pain; avoid co-prescribing with opioids due to overdose risk and antagonism of analgesia (Friedman et al., 2019).
• Carisoprodol carries dependence risk (Reeves et al., 2012).
• Baclofen (GABA-B agonist) is reserved for spasticity; abrupt withdrawal can be dangerous (Coffey et al., 1991).

My guideline:

• Reserve short-term, low-dose use for clear spasm interfering with sleep or movement initiation.
• Prioritize integrative chiropractic, soft-tissue strategies, and neuromuscular reeducation to address root causes.

Balancing Body and Metabolism- Video

Opioids: Mechanisms, Cytochrome P450 Variability, and Safer Prescribing

Opioids remain necessary for select cases but require careful pharmacologic oversight.

Mechanisms:

• Mu receptor activation reduces nociceptive transmission in the CNS; delta and kappa receptors contribute variably to analgesia and side effects (Stein, 2016).
• Respiratory depression is the leading safety concern; risk increases with sedatives, sleep apnea, and high doses.

Cytochrome P450 metabolism matters:

• CYP2D6 converts codeine to morphine and influences oxycodone’s analgesic metabolites; poor metabolizers get less relief, ultra-rapid metabolizers risk toxicity (Crews et al., 2014).
• CYP3A4 metabolizes agents like oxycodone and fentanyl; inhibitors elevate levels; inducers reduce efficacy.
• Morphine and hydromorphone primarily undergo UGT glucuronidation (UGT2B7), offering alternatives when CYP variability complicates outcomes (Dean, 2004).

Clinical strategies:

• Avoid codeine in children or unknown CYP2D6 status.
• Prefer morphine or hydromorphone if CYP interactions complicate oxycodone predictability.
• Consider buprenorphine for chronic pain in high-risk profiles; its partial mu agonism and kappa antagonism limit respiratory depression with a ceiling effect (Dahan et al., 2005).
• Methadone’s NMDA antagonism can help neuropathic pain and opioid hyperalgesia, but its variable half-life and QT prolongation risk require ECG monitoring and slow titration (Krantz et al., 2002; Chou et al., 2014).

Monitoring and risk mitigation:

• Tie opioid trials to functional goals and frequent reassessment.
• Perform PDMP checks, use agreements, co-prescribe naloxone, implement bowel regimens, and screen for sleep apnea.
• Plan exit strategies and rotation if tolerance or adverse events occur.

Integration with chiropractic: When pain blocks movement, carefully selected opioids can open a therapeutic window for manual therapy, graded loading, and neuromuscular reeducation—always with an exit plan.

Low-Dose Naltrexone: Microglial Modulation for Central Sensitization

Low-dose naltrexone (LDN, 1.5–4.5 mg) exerts paradoxical benefits distinct from its high-dose use in addiction. It appears to reduce neuroinflammation by modulating microglia and toll-like receptor signaling, and may enhance endogenous opioid tone over time (Younger et al., 2014; Patten et al., 2017).

Evidence and indications:

• Fibromyalgia: small trials show reduced pain and improved quality of life (Younger et al., 2013; Cree et al., 2020).
• Long COVID: observational signals of improved fatigue and dysautonomia (Bonilla et al., 2023).
• Crohn’s disease: studies suggest mucosal healing and improved endoscopic scores in some patients (Smith et al., 2011; Agrawal et al., 2017).

Dosing and safety:

• Start 1.5 mg nightly; titrate to 3–4.5 mg as tolerated.
• Side effects: vivid dreams, insomnia, transient headaches; dose timing adjustments can help.
• In acute settings, sufficient opioid dosing can overcome transient receptor antagonism.

Integration with chiropractic and functional medicine: By lowering neuroinflammatory “noise,” LDN can enhance tolerance to movement-based therapies. We pair LDN with anti-inflammatory nutrition, gut repair, and sleep optimization to address central sensitization comprehensively.

Suzetrigine: A New Non-Opioid for Acute Pain

Suzetrigine is a peripherally acting analgesic that targets the Nav1.8 sodium channel on nociceptors, reducing pain signal propagation without mu-opioid receptor engagement (McDermott et al., 2019; Alexandrou et al., 2016). Approved in early 2025 for acute pain, it offers an opioid-sparing option.

Key points:

• Dosing used in trials: 100 mg loading, then 50 mg twice daily for up to two weeks.
• Analgesia approached hydrocodone 5 mg twice daily in trials without outperforming it, yet with a non-opioid safety profile.
• Notable consideration: may reduce oral contraceptive efficacy—patients need alternative contraception for at least a month.

Integration with chiropractic:

• Facilitates early mobilization and active rehab without opioid-related sedation or psychomotor slowing.
• Useful for acute musculoskeletal injuries, sprains, and post-acute flare-ups where opioids are undesirable.

Access caveats: Payers may require prior failure with hydrocodone for coverage—an ironic obstacle for a non-scheduled agent.

Benzodiazepines and Opioids: A Risky Pair With Analgesic Antagonism

My stance is firm: benzodiazepines are not pain medicines. Their limited role in muscle spasm and anxiety must be weighed against significant risks:

• Co-prescribing benzodiazepines and opioids dramatically increases overdose risk; synergy at brainstem respiratory centers reduces compensatory responses to hypercapnia (Park et al., 2015; Sun et al., 2017).
• Evidence indicates benzodiazepines can blunt opioid analgesia, prompting dose escalation and greater sedation risk (Pergolizzi et al., 2018).
• Diazepam offers minimal benefit for acute low back pain and is not helpful for sciatica (Friedman et al., 2019).

Our approach:

• Prefer CBT, SSRIs/SNRIs, sleep hygiene, and mindfulness for anxiety.
• If a short benzodiazepine course is unavoidable, keep doses minimal and durations brief; avoid co-escalation with opioids; co-prescribe naloxone; schedule close follow-up.

Integration with chiropractic: As we reduce pain generators and autonomic arousal, the need for sedatives often diminishes. Restoring movement confidence reduces hypervigilance and panic around pain.

Building Multimodal Regimens: Mechanistic Logic and Layered Relief

Effective pain care covers multiple nodes in the pain network:

• Peripheral inflammation: topical or oral NSAIDs (if safe).
• Central sensitization: gabapentinoids, LDN where appropriate.
• Descending inhibition deficits: SNRIs, TCAs.
• Ectopic discharges: lidocaine patches, capsaicin desensitization.
• Sleep restoration: low-dose TCA or short-term muscle relaxant.
• Acute breakthroughs: short-acting opioids—only within a structured plan emphasizing function.
• Integrative chiropractic: spinal/extremity adjustments, soft-tissue therapies, graded motor control, and movement retraining form the backbone.

We tailor regimens to individual mechanisms, comorbidities, and functional targets, adjusting as data and outcomes evolve.

Functional Medicine Integration: Biochemistry of Pain and Recovery Capacity

Pain physiology is profoundly shaped by metabolism, nutrition, and sleep:

• Omega-3s reduce inflammatory mediators and support membrane function, offering NSAID-sparing benefits (Calder, 2013).
• Glycemic control helps neuropathy management and reduces oxidative stress.
• Vitamin D supports muscle function and neuromodulation (Zhu et al., 2019).
• Gut-liver axis disturbances can perpetuate systemic inflammation; targeted nutrition, probiotics, and gut-repair nutrients can modulate the gut-brain axis (Mayer et al., 2015; De Punder & Pruimboom, 2015).
• Sleep continuity empowers descending inhibition and tissue repair; we deploy CBT-I principles and circadian alignment.

This metabolic foundation improves analgesic responsiveness and reduces the need for pharmacologic escalation.

Behavioral Health and Pain Education: Resetting the Threat Response

Pain neuroscience education reframes pain as modifiable physiology, decreasing fear and catastrophizing. We coordinate:

• CBT and ACT to reduce avoidance and increase function.
• Mindfulness and HRV biofeedback to improve vagal tone and dampen sympathetic drive.

These interventions enhance the effectiveness of manual therapy and medication by calming the CNS and building self-efficacy.

Personal Injury Care: Documentation, Mechanism, and Return-to-Function

In personal injury cases, precision matters:

• Mechanism-of-injury analysis aligns kinematics and tissue loads with findings.
• Impairment ratings and function-based outcomes track recovery and guide fair settlements.
• Return-to-work plans use graded exposure and ergonomic coaching to reduce re-injury risk.

Our integrated approach limits chronicity by engaging patients early in movement-based recovery under medical oversight.

Synergistic Timing: How We Sequence Treatments Through Pain Phases

We align the right treatments with the right phase:

• Acute phase: topical NSAIDs, short NSAID courses if safe, sleep protection via a short-term muscle relaxant, gentle manual therapy, and breathing strategies.
• Subacute phase: gabapentinoids or SNRIs for neuropathic or centralized features; progressive chiropractic mobility and corrective exercise; begin functional nutrition.
• Chronic phase: consolidate gains, taper medications, reinforce movement patterns, incorporate behavioral strategies, and consider interventional options if needed.

We schedule follow-ups with medication titration checkpoints and coordinate sessions to align with peak analgesia for optimal rehab.

Example Care Pathways: Translating Mechanisms to Action

Lumbar radiculopathy:

• Topical diclofenac over affected paraspinals and referral
• Slowly titrate gabapentin if tolerable, acetaminophen adjunct for central modulation.
• Gabapentin slow titration to diminish dorsal horn hyperexcitability.
• Chiropractic flexion-distraction for disc loading relief and neural gliding.
• Sleep focus; duloxetine added if significant central sensitization persists.
• Functional goals: walk 20 minutes, complete sit-stand cycles, lift 10–20 lb without flare.

Chronic neck pain with headache:

• Low-dose amitriptyline at bedtime for sleep and descending inhibition.
• Postural correction, deep neck flexor training, scapular control, and soft-tissue release.
• Capsaicin for focal sensitization where tolerated; lidocaine patch for localized neuropathic spots.
• Short-term tizanidine at night when spasm is evident, tapered as control improves.

Osteoarthritis knee:

• Topical diclofenac as first-line; acetaminophen for breakthrough.
• Duloxetine for centralized features; weight management and omega-3 enrichment.
• Chiropractic extremity mobilization, quadriceps and hip abductor strengthening; gait retraining.
• Pain education and pacing strategies.

Opioid-Induced Constipation: Treating the Gut Without Losing Analgesia

Opioids activate mu receptors in the enteric nervous system, slowing motility and increasing fluid absorption—leading to constipation.

Practical steps:

• Avoid bulk-forming agents when motility is impaired—they can worsen obstruction.
• Use PAMORAs (methylnaltrexone, naloxegol, naldemedine) to antagonize peripheral mu receptors without crossing the BBB, restoring motility without reversing analgesia (Chey et al., 2014; Webster et al., 2017).
• Apply osmotic laxatives (PEG), stool softeners (docusate), and hydration where appropriate.
• If obstruction is suspected, obtain an abdominal flat plate.

Integration with chiropractic and rehab: Gentle movement, core activation, diaphragmatic breathing, and anti-inflammatory diets improve bowel function when peristalsis is pharmacologically supported.

Naloxone as a Household Safety Tool: Risk Mitigation Saves Lives

Naloxone is for a risky drug, not a risky patient. We normalize naloxone provision:

• Over-the-counter access expands reach; caregivers are trained to recognize overdose and administer promptly.
• Redosing may be required; withdrawal is uncomfortable but preferable to fatal respiratory depression (Coffin et al., 2016).
• Safe storage should be emphasized alongside safe storage of opioids.

In parallel, we reduce opioid doses through improved biomechanics and metabolic health, lowering overall risk.

Practical Dosing: When Timing Is the Fix

Daily “pain spikes” often reflect mismatched dosing schedules rather than drug failure. We:

• Map pain peaks against daily activity and timing.
• Shift dose timing to cover predictable flares (e.g., mid-afternoon dose at 3 pm instead of noon).
• Coordinate therapy sessions when analgesia is adequate to support graded loading.

Small adjustments in timing can achieve large functional wins without changing the medication itself.

Safe Storage and Disposal: Preventing Diversion and Harm

Leftover opioids pose a household risk. We:

• Encourage take-back programs; if unavailable, follow FDA disposal guidance—including flushing for certain high-risk drugs (FDA, 2020).
• Provide written storage and disposal instructions.
• Consider starter kits integrating naloxone and clear safety education (Kennedy-Hendricks et al., 2016).

Real-World Profiles: How Mechanistic Care Helps “Mike” and “Sheila”

Mike (56): construction worker with lumbar disc bulges, facet arthropathy, post-MI on anticoagulants. He maintains function with hydrocodone once or twice daily and receives episodic epidurals. Muscle relaxants are avoided to preserve cognition at work.

• Integrative plan: segmental mobilization, flexion-distraction, hip-pelvic mechanics, core stabilization; anti-inflammatory nutritional plan mindful of anticoagulants; align analgesic timing with work demands; avoid benzos.
• Outcome goal: reduced opioid reliance with safe, sustained work capacity.

Sheila (84): L4–S1 fusion, adjacent segment degeneration, poor bone density, respiratory issues. An older spinal cord stimulator eased radicular pain but not axial low back pain. Maintained on extended-release oxycodone with short-acting Percocet for breakthrough.

• Integrative plan: gentle mobilization above/below fusion; myofascial release; pelvic tilt optimization; fall-risk reduction; pain education; consider buprenorphine patch to reduce respiratory risk; evaluate newer neuromodulation; coordinate with Dr. Cardenas for respiratory and bone health.
• Outcome goal: safer analgesia with better balance, fewer falls, and improved daily function.

These profiles exemplify the layered, safety-conscious approach we implement in our clinic.

Spinal Cord Stimulation: Evolving Technology for Axial and Radicular Pain

Traditional SCS is more effective for radicular pain than axial back pain. Newer high-frequency and burst stimulation show improved axial outcomes (Deer et al., 2017). Our role:

• Reassess candidacy in the context of current function and comorbidities.
• Integrate manual therapy and rehab to maximize neuromodulation benefits.
• Coordinate monitoring with internal medicine oversight.

The Science of Why Integrative Care Works: Multilevel Targeting and Redundancy

Combining chiropractic, internal medicine, functional medicine, and rehabilitation works because:

• We target multiple levels—biomechanical, cellular, neuroimmune, and behavioral—creating redundancy so if one path lags, others propel progress.
• Medical oversight detects adverse trends early; chiropractic ensures safe movement; functional medicine reduces inflammatory load; rehab builds capacity and confidence.
• Continuous learning cycles let us iterate based on objective function metrics and validated tools.

Safety Culture: Risk Assessments, Agreements, Monitoring

To guard against harm while pursuing relief, we:

• Use validated tools (SOAPP-R, COMM) to profile misuse risk (Butler et al., 2007; McCaffery et al., 2005).
• Employ medication agreements clarifying expectations, monitoring, and refills.
• Conduct PDMP checks and schedule frequent reviews.
• Document prior therapies and contraindications (e.g., NSAIDs avoided due to anticoagulants).
• Provide naloxone and educate on overdose recognition.

This infrastructure allows compassionate care within a protective safety envelope.

Coordinated Care With Dr. Maria Guadalupe Cardenas, MD: Internal Medicine Oversight

Dr. Cardenas, our Medical Director and Collaborative Physician (NPI #1164426749; Texas MD License #J2933), ensures:

• Drug-drug interaction checks (CYP, QT prolongation).
• Lab monitoring (renal, hepatic), ECGs when indicated.
• Comorbidity management (hypertension, diabetes, anticoagulation).
• Imaging pathways and referral coordination.
• Hospital transitions and continuity of care.

Her comprehensive internal medicine lens is indispensable to the safe execution of an integrative pain plan.

Rehabilitation Strategies: Active Recovery Over Passive Dependency

We prioritize active care:

• Graded exposure: carefully increase load to reduce fear and build capacity.
• Motor control: lumbo-pelvic stabilization, hip hinge patterns, scapular mechanics.
• Myofascial strategies: trigger point release, instrument-assisted soft-tissue mobilization.
• Conditioning: tailored aerobic base-building with micro-progressions.

These elements help patients reclaim function while reducing medication burden.

How We Decide: A Stepwise Algorithm In Practice

• Confirm pain generator(s): mechanical, inflammatory, neuropathic, centralized.
• Stabilize red flags: infection, fracture, cauda equina, progressive deficits.
• Initiate integrative care: chiropractic normalization, anti-inflammatory nutrition, sleep support.
• Add pharmacologic adjuncts:

• Prefer non-opioids first: topical/NSAIDs (if safe), acetaminophen, duloxetine for chronic musculoskeletal pain, suzetrigine for acute pain.
• If opioids needed: lowest effective dose, functional goals, naloxone provision.
• Avoid benzodiazepines; if necessary, minimal dose/duration with close monitoring.
• Short-term muscle relaxants only for spasm; not for radicular pain.
• Consider LDN for fibromyalgia-like syndromes, long COVID features, and selected gastrointestinal inflammatory conditions.
• Buprenorphine patches for elderly or high-risk patients; methadone cautiously with ECG oversight for refractory mixed pain.

• Treat OIC proactively (PAMORAs).
• Align dosing schedules with daily activity cycles.
• Reassess monthly using function and safety metrics.

Patient Education: Clear, Consistent, Empowering

We anchor care with transparent communication:

• Risks and benefits explained in practical terms.
• Written instructions for storage and disposal.
• Pain neuroscience education to lower fear and build self-management skills.
• Lifestyle coaching on nutrition, sleep, stress, and movement.

Education creates lasting change; our words are medicine, too.

Clinical Observations From My Practice

From my work chronicled at HealthCoach Clinic (healthcoach.clinic/) and my professional updates (www.linkedin.com/in/dralexjimenez/), I repeatedly observe:

• Movement-based care reduces medication escalation and yields more stable outcomes.
• Sleep normalization magnifies analgesic effects by restoring descending inhibition.
• Low-dose naltrexone shows promise in fibromyalgia-like syndromes when paired with anti-inflammatory nutrition and sleep strategies.
• Buprenorphine patches help elderly patients maintain function with fewer falls and less confusion compared to full mu agonists.
• Tactical dose timing often resolves daily spikes without changing drugs.
• PAMORAs significantly improve adherence by relieving OIC.
• Interdisciplinary MD-DC collaboration reduces errors and improves outcomes for complex patients.

These observations reinforce evidence-based protocols and inspire ongoing refinement.

Conclusion: A Compassionate, Mechanism-Driven Pathway That Works

Pain care is personal and complex. By mapping treatments to physiology, aligning medications with integrative chiropractic care and rehabilitation, and coordinating under internal medicine oversight, we deliver safer, smarter plans. In our clinic, medications are stepping stones, not endpoints. Function is the currency of success. Expectations are reset; progress is layered; outcomes are meaningful.

Thank you for joining me on this journey toward modern, integrated, evidence-based pain management. Our shared goal is to restore movement, reduce risk, and help people live more fully—with clarity, compassion, and science guiding every step.

References

• Alexandrou, A. J., et al. (2016). 7 and Nav1.8 in human pain. Science Translational Medicine.
• Agrawal, A., Pulik, M., & Garg, S. K. (2017). Low-dose naltrexone for Crohn’s disease: A systematic review. Journal of Clinical Gastroenterology.
• Bhala, N., Emberson, J., Merhi, A., et al. (2013). Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs. The Lancet.
• Bialosky, J. E., Bishop, M. D., Price, D. D., Robinson, M. E., & George, S. Z. (2009). The mechanisms of manual therapy in musculoskeletal pain. Manual Therapy.
• Bjarnason, I., Scarpignato, C., Takeuchi, K., & Rainsford, K. D. (2018). Determinants of the short-term tolerability of NSAIDs. Inflammopharmacology.
• Bonilla, H., Gomes, C., & Asif, T. (2023). Low-dose naltrexone for treatment of long COVID. Journal of Investigative Medicine High Impact Case Reports.
• Browning, R., Jackson, J. L., O’Malley, P. G., & Chew, P. (2001). Cyclobenzaprine for muscle spasm. Archives of Internal Medicine.
• Butler, S. F., Budman, S. H., Fernandez, K. C., et al. (2007). Development and validation of the SOAPP-R. The Journal of Pain.
• Calder, P. C. (2013). Omega-3 polyunsaturated fatty acids and inflammatory processes. British Journal of Clinical Pharmacology.
• Chappell, A. S., Desaiah, D., Liu-Seifert, H., et al. (2011). Duloxetine in chronic low back pain. Spine.
• Chaparro, L. E., Wiffen, P. J., Moore, R. A., & Gilron, I. (2012). Lamotrigine for chronic neuropathic pain and fibromyalgia. Cochrane Database of Systematic Reviews.
• Chey, W. D., Webster, L., Sostek, M., et al. (2014). Naloxegol for opioid-induced constipation. New England Journal of Medicine.
• Chou, R., Ballantyne, J., Fanciullo, G., et al. (2009). Clinical guidelines for use of chronic opioid therapy. The Journal of Pain.
• Chou, R., Cruciani, R. A., Fiellin, D. A., et al. (2014). Methadone safety: A clinical practice guideline. Journal of Pain.
• Cleeland, C. S. (2009). The Brief Pain Inventory: User guide. MD Anderson Cancer Center.
• Coffey, R. J., Edgar, T. S., Francisco, G. E., et al. (1991). Abrupt withdrawal from intrathecal baclofen. The Lancet.
• Coffin, P. O., Behar, E., Rowe, C., et al. (2016). Naloxone distribution and overdose prevention. Annals of Internal Medicine.
• Crews, K. R., Gaedigk, A., Dunnenberger, H. M., et al. (2014). CPIC guidelines for CYP2D6 genotype and codeine therapy. Clinical Pharmacology & Therapeutics.
• Dahan, A., Yassen, A., Romberg, R., et al. (2005). Buprenorphine induces a ceiling in respiratory depression but not analgesia. British Journal of Anesthesia.
• Deer, T. R., Mekhail, N., Provenzano, D., et al. (2017). The appropriate use of neurostimulation. Neuromodulation.
• Dean, L. (2004). Morphine therapy and UGT2B7. NCBI Bookshelf.
• Derry, S., Conaghan, P., Da Silva, J. A., et al. (2016). Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database of Systematic Reviews.
• Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., Chou, R., & CDC. (2022). CDC clinical practice guideline for prescribing opioids for pain — United States, 2022. MMWR.
• Eccles, R., & Turner, R. (2009). Capsaicin: The hot chili pepper for pain therapy. Therapeutic Advances in Drug Safety.
• Evoy, K. E., Sadrameli, S., Contreras, J., Covvey, J. R., & Saklad, S. R. (2021). Abuse and misuse of gabapentin and pregabalin. Drugs.
• (2018). Suicidality in children and adolescents being treated with antidepressant medications.
• (2020). Disposal of unused medicines: What you should know.
• Flockhart, D. A. (2007). Cytochrome P450 drug interaction table. Indiana University.
• Friedman, B. W., Irizarry, E., Solorzano, C., et al. (2019). Diazepam vs placebo as adjunct to NSAIDs for acute low back pain. Annals of Emergency Medicine.
• Gatti, A., Lazzari, M., Tufaro, L., Barbagli, R., Paoletti, F., Sabato, A. F., & Sabato, E. (2021). Efficacy and safety of duloxetine in chronic musculoskeletal pain. Clinical Therapeutics.
• Goodman, C. W., & Brett, A. S. (2019). A clinical overview of gabapentin and pregabalin. Journal of Clinical Psychiatry.
• Goodman, C. W., & Brett, A. S. (2019). A clinical overview of serotonin syndrome. Biological Psychiatry.
• Grace, P. M., Hutchinson, M. R., Maier, S. F., & Watkins, L. R. (2014). Pathological pain and the neuroimmune interface. Nature Reviews Immunology.
• Högestätt, E. D., et al. (2005). Conversion of acetaminophen to AM404 via FAAH in the brain. Journal of Biological Chemistry.
• Hofmann, S. G., Asnaani, A., Vonk, I. J., et al. (2012). CBT for anxiety disorders: A meta-analysis. Cognitive Therapy and Research.
• Jones, J. D., Mogali, S., & Comer, S. D. (2012). Polydrug abuse: Benzodiazepines and opioids. Drug and Alcohol Dependence.
• Kennedy-Hendricks, A., Gielen, A. C., McDonald, E. M., et al. (2016). Opioid leftovers after surgery and sharing. JAMA Surgery.
• Khaliq, W., Alam, S., & Puri, N. (2007). Topical lidocaine for neuropathic pain in adults. Cochrane Database of Systematic Reviews.
• Krantz, M. J., Lewkowiez, L., Hays, H., et al. (2002). Torsade de pointes associated with methadone. Circulation.
• Lanas, A., & Chan, F. K. L. (2017). Peptic ulcer disease. The Lancet.
• Lee, W. M. (2017). Acute liver failure due to acetaminophen poisoning. Seminars in Liver Disease.
• Mayer, E. A., Tillisch, K., & Gupta, A. (2015). Gut/brain axis and pain. Nature Reviews Gastroenterology & Hepatology.
• McCaffery, M., Pasero, C., & Ferrell, B. (2005). Behavioral health monitoring tools (COMM). Pain Management Nursing.
• McDermott, L. A., Weir, G., & Bennett, D. L. (2019). Sodium channelopathies in pain. Annual Review of Neuroscience.
• Melzack, R., & Wall, P. D. (1965). Pain mechanisms: A new theory. Science.
• Millan, M. J. (2002). Descending control of pain. Progress in Neurobiology.
• Milligan, E. D., & Watkins, L. R. (2009). Pathological and protective roles of glia in chronic pain. Nature Reviews Neuroscience.
• Moore, R. A., Derry, S., Aldington, D., et al. (2015). Amitriptyline for neuropathic pain in adults. Cochrane Database of Systematic Reviews.
• Park, T. W., Saitz, R., Ganoczy, D., Ilgen, M. A., & Bohnert, A. S. (2015). Benzodiazepine prescribing patterns and overdose mortality among patients receiving opioids. BMJ.
• Patten, D. K., Schultz, B. G., & Berlau, D. J. (2017). The safety and efficacy of low-dose naltrexone. Clinical Pharmacology: Advances and Applications.
• Pergolizzi, J. V., LeQuang, J. A., Taylor, R., Jr., Raffa, R. B., & NEMA Research Group. (2018). Managing benzodiazepines and opioids together. Journal of Clinical Pharmacy and Therapeutics.
• Pini, L. A., et al. (1997). Antinociceptive activity of paracetamol: Role of 5-HT3 receptors. European Journal of Pharmacology.
• Qaseem, A., Wilt, T. J., McLean, R. M., & Forciea, M. A. (2017). Noninvasive treatments for acute, subacute, and chronic low back pain. Annals of Internal Medicine.
• Reeves, R. R., Parker, J. D., & Burke, R. S. (2012). Carisoprodol tolerance and dependence. Journal of Addictive Diseases.
• Roberts, E., et al. (2016). Paracetamol: Not as safe as we thought?. Annals of the Rheumatic Diseases.
• Smith, H. S., & Laufer, A. (2010). Tizanidine in musculoskeletal pain. Pain Physician.
• Smith, C. J., Kim, D. H., & Spanier, B. (2011). Low-dose naltrexone improved CCrohn’sdisease activity. Digestive Diseases and Sciences.
• Stein, C. (2016). Opioid receptors. Annual Review of Medicine.
• Sun, E. C., Dixit, A., Humphreys, K., Darnall, B. D., Baker, L. C., & Mackey, S. (2017). Association between concurrent use of prescription opioids and benzodiazepines and overdose. BMJ.
• Taylor, C. P., Angelotti, T., & Fauman, E. (2007). Pharmacology and mechanism of action of pregabalin. CNS Drug Reviews.
• van Tulder, M. W., Touray, T., Furlan, A. D., Solway, S., & Bouter, L. M. (2003). Muscle relaxants for non-specific low-back pain. Cochrane Database of Systematic Reviews.
• Webster, L., Slatkin, N., Patel, H., et al. (2017). Naldemedine for opioid-induced constipation. The Journal of Pain.
• Woolf, C. J. (2011). Central sensitization: Implications for diagnosis and treatment of pain. Pain.
• Younger, J., Noor, N., McCue, R., & Mackey, S. (2013). Low-dose naltrexone for fibromyalgia: A small randomized trial. Arthritis & Rheumatism.
• Younger, J., Parkitny, L., & McLain, D. (2014). Low-dose naltrexone as a novel anti-inflammatory treatment. Clinical Rheumatology.
• Zhu, K., et al. (2019). Vitamin D and musculoskeletal health. Maturitas.

SEO tags: integrative pain management, chiropractic integrative care, internal medicine oversight pain clinic, Dr Maria Guadalupe Cardenas MD, Dr Alex Jimenez DC APRN FNP-BC, El Paso pain clinic, pharmacology for pain, acetaminophen safety, NSAIDs GI cardiovascular risk, topical diclofenac lidocaine capsaicin, gabapentin pregabalin neuropathic pain, duloxetine chronic musculoskeletal pain, tricyclic antidepressants pain sleep, benzodiazepines opioids overdose risk, buprenorphine methadone pain, cytochrome P450 opioid metabolism, opioid-induced constipation PAMORA, low-dose naltrexone microglia fibromyalgia, suzetrigine Nav1.8 non-opioid analgesic, spinal cord stimulation chronic pain, functional medicine gut-brain axis, central sensitization descending inhibition, evidence-based pain protocols, personal injury rehabilitation, HealthCoach Clinic observations, multidisciplinary chiropractic medical clinic